Myriad Genetics (NASDAQ: MYGN) insider transactions
In the twelve months to 10 November 2026, executives and directors of Myriad Genetics reported 1 open-market sale of 15,000 shares ($66,900) and 5 open-market purchases of 152,007 shares ($722,223), by 4 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 1 November 2026 | Fox Jennifer Lynne | Chief Legal & Corp Strategy | Grant or award | +39,370 | — | 345,334 | Form 4 |
| 21 September 2026 | Wheeler Benjamin Richard | Chief Financial Officer | Shares withheld for tax | −2,555 | $4.01 | 287,193 | Form 4 |
| 16 September 2026 | Sikri Vishal | EVP, Commercial | Grant or award | +257,731 | — | 351,224 | Form 4 |
| 3 September 2026 | Fox Jennifer Lynne | Chief Legal Officer | Shares withheld for tax | −4,398 | $3.23 | 305,964 | Form 4 |
| 16 August 2026 | Wheeler Benjamin Richard | Chief Financial Officer | Shares withheld for tax | −8,761 | $3.03 | 289,748 | Form 4 |
| 11 June 2026 | Raha Samraat S. | President and CEO | Grant or award | +3,542 | $3.94 | 1,068,083 | Form 4 |
| 11 June 2026 | Donnelly Brian J | Chief Commerical Officer | Grant or award | +5,000 | $3.94 | 573,363 | Form 4 |
| 8 June 2026 | Kumar Rashmi | Director | Open-market sale, 10b5-1 plan | −15,000 | $4.46 | 171,889 | Form 4 |
| 4 June 2026 | Bisaro Paul | Director | Grant or award | +59,701 | — | 157,142 | Form 4 |
| 4 June 2026 | Dreismann Heinrich | Director | Grant or award | +59,701 | — | 231,145 | Form 4 |
| 4 June 2026 | Phanstiel S. Louise | Director | Grant or award | +59,701 | — | 341,652 | Form 4 |
| 4 June 2026 | Skovronsky Daniel | Director | Grant or award | +59,701 | — | 195,507 | Form 4 |
| 4 June 2026 | Reitan Colleen F | Director | Grant or award | +59,701 | — | 152,030 | Form 4 |
| 4 June 2026 | Newcomer Lee Nisley | Director | Grant or award | +59,701 | — | 191,842 | Form 4 |
| 4 June 2026 | Kumar Rashmi | Director | Grant or award | +59,701 | — | 186,889 | Form 4 |
| 4 June 2026 | Davis Mark Steven | Director | Grant or award | +59,701 | — | 106,665 | Form 4 |
| 1 June 2026 | Jampa Raj | Chief Technology Officer | Grant or award | +251,889 | — | 251,889 | Form 4 |
| 14 May 2026 | Bisaro Paul | Director | Open-market purchase | +7,500 | $3.69 | 97,441 | Form 4 |
| 1 May 2026 | Donnelly Brian J | Chief Commerical Officer | Shares withheld for tax | −55,975 | $4.80 | 568,363 | Form 4 |
| 14 April 2026 | Verratti Mark | Chief Operating Officer | Shares withheld for tax | −1,069 | $4.91 | 629,646 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Myriad Genetics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.